article thumbnail

Ortho-Phthalates Retain FDA Approval for Food Packaging Despite Petitions

XTalks

Last week, the US Food and Drug Administration (FDA) stood by its decision, denying a petition asking it to reevaluate the use of eight ortho-phthalates in food-contacting packaging materials. Related: Is Fiber Based Packaging the Next Trend in Sustainable Food Packaging?

article thumbnail

Celltrion’s Yuflyma receives US FDA approval for multiple conditions

Pharmaceutical Technology

It is already the first proposed high-concentration (100mg/mL), low-volume and citrate-free adalimumab biosimilar in the world to receive marketing authorisation from the European Commission. Yuflyma represents the company’s fifth biosimilar and second anti-TNF biosimilar to receive US FDA approval.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ortho-Phthalates in Food Packaging + McDonald’s New Restaurant Idea – Xtalks Food Podcast Ep. 121

XTalks

Last month, the US Food and Drug Administration (FDA) stood by its decision, denying a petition asking it to reevaluate the use of eight ortho-phthalates in food-contacting packaging materials. But recently, the company has struck gold with its character-based marketing.

article thumbnail

Lung Disease Diagnostic Xenoview Gets FDA Approval for Use with MRI

XTalks

According to Polarean, Xenoview is the first and only inhaled hyperpolarized MRI contrast agent to reach the market. Xenoview is a 129 Xe gas blend; it is packaged in a dose delivery bag and thus can be inhaled by a patient during a single breath hold MRI procedure (10 to 15 seconds long).

article thumbnail

Merck’s Winrevair Wins FDA Approval as First-in-Class Treatment for Pulmonary Arterial Hypertension (PAH)

XTalks

The US Food and Drug Administration (FDA) has given the nod to Winrevair (sotatercept-csrk injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension (PAH) to increase exercise capacity, improve WHO (World Health Organization) functional class (FC) and reduce the risk of clinical worsening events. billion in 2032.

article thumbnail

FDA approves GSK’s Blenrep for advanced multiple myeloma

pharmaphorum

Blenrep (belantamab mafodotin) has been approved in patients who have received at least four therapies including an anti-CD38 such as Darzalex, a proteasome inhibitor and an immunomodulatory agent. The post FDA approves GSK’s Blenrep for advanced multiple myeloma appeared first on. of patients in the cohort.

article thumbnail

CMO Moves: Regulatory Catalysts for Drug Manufacturing-November

Pharmaceutical Technology

These contracts involve the manufacturing of biological and small molecule active pharmaceutical ingredients (APIs), parenteral manufacturing and packaging, and other manufacturing-related tasks. The EMA had provided a positive opinion for this marketing authorization back in July. Regulatory decisions come in. NICE decisions.